MEK inhibition in TNBC cell lines, genetically engineered mice, and human tumor samples has been shown to induce dynamic reprogramming of the kinome, which is target-specific and clearly different from that induced by other target therapies such as PI3K/mTOR inhibitors. Here, MAP2K7 is linked to neoplasm.